About FSHD Canada Foundation

FSHD clinical trials are coming to Canada – get registered here: Canadian Neuromuscular Disease Registry

Funded Research

Please note that any funds granted from the FSHD Canada Foundation cannot be used to cover more than ten percent (10%) of overhead costs.

Phenotypic characterization of FSHD-like FLExDUX4 minipigs

Investigator: Peter L. Jones, PhD, University of Nevada, Reno School of Medicine All forms of FSHD are caused by misexpression of DUX4 (double homeobox protein 4) in skeletal muscles; thus, the…

Read More

Matrix Bound Nanovesicles (MBV) as a Therapy for FSHD

Investigator: Dr. George Hussey, University of Pittsburgh Regenerative Medicine provides an alternative FSHD treatment strategy for promoting new tissue growth using Extracellular Matrix (ECM) bioscaffolds. ECM bioscaffolds serve as a biochemical…

Read More

Working Towards an ASO Treatment for FSHD2 Patients

Investigator: Dr. Stanley Crooke FSHD is a rare disease. FSHD2 is even more rare. Only 5% of all FSHD patients have FSHD2. We don’t want them to get left behind. The…

Read More

Accelerating Canadian Regulatory Approvals

The Objective Several promising treatments for FSHD are going into clinical trials very soon. Hopefully, these therapies will be approved for use by FSHD patients in the next couple of…

Read More

Diagnostics

Investigator Takako Jones, PhD (University of Nevada, Reno School of Medicine) Current FSHD diagnostics are complex, expensive, and not widely available. In addition, the disease itself has wide variability in…

Read More

Biomarkers

Investigators: Yi-Wen Chen (Children’s National Hospital, Washington, DC) Giorgio Tasca & Enzo Ricci (Università Cattolica del Sacro Cuore – Rome) Sabrina Sacconi (Centre Hospitalier Universitaire de Nice) Biomarkers are used…

Read More
https://twitter.com/#!/FSHDCanada/ http://www.facebook.com/pages/FSHD-Canada/331378503625267 /contact Suite 201, 1100 1st St. SE Calgary, Alberta T2G 1B1 403.470.0141 neil.camarta@fshd.ca